SISVEL-INTERNATIONAL
14.4.2020 14:27:08 CEST | Business Wire | Press release
Sisvel International S.A. (“Sisvel”) announced today the launch of its “MIOTY” Licensing Platform, a new joint patent licensing effort for the MIOTY technology. The platform has been launched with patents owned, or controlled by, Fraunhofer-Institute for Integrated Circuits IIS (“Fraunhofer IIS”) and Diehl Metering GmbH (“Diehl”).
Fraunhofer IIS and Diehl are working together under the brand name MIOTY in the area of wireless technology for low power wide area networks (“LPWAN”). MIOTY technology is based on the protocol family Telegram Splitting Ultra Narrow band (“TS-UNB”) of the ETSI standard TS 103 357 (“TS-UNB Specification”).
Sisvel is organizing this licensing platform to make MIOTY technology accessible on fair, reasonable, and non-discriminatory terms and conditions by offering a royalty-bearing, non-transferable, non-assignable, non-exclusive license, with no right to grant sublicenses, under patents essential to the TS-UNB Specification. In addition, Sisvel offers a license to patents complementary to MIOTY implementations.
Further information about the terms and conditions of Sisvel’s MIOTY licenses are available on Sisvel’s website https://www.sisvel.com/licensing-programs/wireless-communications/mioty/introduction
. For more details you may contact Sisvel at the following e-mail address MIOTY@sisvel.com
.
The MIOTY Licensing Platform remains open to additional patent owners with relevant patents. Thus, Sisvel invites all parties that have patents or patent applications they believe to be essential to the protocol family TS-UNB of the ETSI standard TS 103 357 to contact Sisvel and submit those patent(s) for an evaluation by the program’s designated, independent evaluators.
About Fraunhofer IIS
The Fraunhofer-Gesellschaft is the leading organization for applied research in Europe. Its research activities are conducted by 74 institutes and research units at locations throughout Germany. The Fraunhofer-Gesellschaft employs a staff of more than 28,000, who work with an annual re-search budget totaling more than 2.8 billion euros.
The Fraunhofer Institute for Integrated Circuits IIS is one of the world’s leading application-oriented research institutions for microelectronic and IT system solutions and services. It is the largest of all Fraunhofer Institutes. Research at Fraunhofer IIS revolves around two guiding topics:
In the area of “Audio and Media Technologies”, the institute has been shaping the digitalization of media for more than 30 years now. Fraunhofer IIS was instrumental in the development of mp3 and AAC and played a significant role in the digitalization of the cinema. Current developments are opening up whole new sound worlds and are being used in virtual reality, automotive sound systems, mobile telephony, streaming and broadcasting.
In the context of “cognitive sensor technologies”, the institute researches technologies for sensor technology, data transmission technology, data analysis methods and the exploitation of data as part of data-driven services and their accompanying business models. This adds a cognitive component to the function of the conventional “smart” sensor.
Nearly 1,100 employees conduct contract research for industry, the service sector and public authorities. Founded in 1985 in Erlangen, Fraunhofer IIS has now 15 locations in 11 cities: Erlangen (headquarters),
Nuremberg, Fürth, Dresden, further in Bamberg, Waischenfeld, Coburg, Würzburg, Ilmenau, Deggendorf and Passau. The budget of 170 million euros is mainly financed by projects. 26 percent of the budget is subsidized by federal and state funds.
Detailed information on: www.iis.fraunhofer.de/en
About Diehl Metering
Diehl Metering is a corporate division of the Diehl Group, headquartered in Nuremberg. With a total annual turnover of 3.75 billion euros, the technology company employs around 17,200 people worldwide. The corporate division Metering supplies solutions for the intelligent use of water, thermal energy, gas and electricity.
Diehl Metering provides smart metering solutions to utilities companies through the intelligent networking of various metering devices into larger data platforms. These solutions offer transparency for utilities and municipalities, and enable considerably increased efficiency in reading, billing and service processes. Diehl Metering’s customers are also able to benefit from real-time effects such as early recognition of leaks and the optimisation of distribution networks through intelligent information regarding prompt adjustment of the offer to suit actual needs.
With Diehl Metering utilities are already perfectly equipped for smart metering as an important component of smart city concepts. Thanks to more than 20 years of experience with the company’s own radio technology, Diehl Metering has at its disposal excellent expertise in communications within the Internet of Things. The MIOTY LPWAN technology has been developed jointly by Fraunhofer IIS and Diehl Metering.
For further information, please visit www.diehl.com/metering
About Sisvel
Sisvel is a world leader in fostering innovation and managing intellectual property. The Group identifies, evaluates and maximizes the value of IP assets for its partners around the world, providing firms with a revenue stream which can be reinvested in innovation for the generation of future revenues. Founded in 1982, the Group is headquartered in Luxembourg and has subsidiaries in China, Germany, Italy, Japan, Spain, the United States and the United Kingdom. The Group has a long history of managing successful patent portfolios including those related to the audio compression standards known as MP3 and MPEG Audio, as well as broadcasting and receiving of digital terrestrial television standards maintained by the DVB Project. Sisvel currently operates patent pools and joint licensing programs in the fields of mobile communication; wireless local area networking 802.11; digital video broadcasting; recommendation engine and broadband access to data networks.
For additional information, please visit: www.sisvel.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200414005501/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 10:01:00 CEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
